Richmond Pharmacology, a specialist early-phase clinical research organization, has announced encouraging results from a first-in-human clinical trial evaluating CIDEBsiRNA, an investigational RNA interference (RNAi) therapy developed by Regeneron Pharmaceuticals, Inc.
